Double-blind, Placebo-controlled, Clinical Trial on Efficacy and Safety of 12-months Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With P. Aeruginosa
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Colistimethate sodium (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Registrational; Therapeutic Use
- Acronyms PROMIS I
- Sponsors Zambon SpA
Most Recent Events
- 12 Sep 2024 According to a Zambon SpA Media Release, results of this study were published in PROMIS-I and PROMIS-II trials.
- 12 Sep 2024 Results presented in a Zambon SpA Media Release.
- 18 Jul 2023 According to a Zambon SpA Media Release, data from this study were presented at the 2023 6th World Bronchiectasis Conference in New York, NY.